Endologix, Inc. (ELGX) Surges to 52-Week High, Is Now Top Performer

June 18, 2018 - By Clifton Ray

Endologix, Inc. (NASDAQ:ELGX) Logo

Investors sentiment decreased to 0.86 in Q1 2018. Its down 0.24, from 1.1 in 2017Q4. It fall, as 12 investors sold Endologix, Inc. shares while 31 reduced holdings. 11 funds opened positions while 26 raised stakes. 81.20 million shares or 6.75% less from 87.08 million shares in 2017Q4 were reported.
Voya Investment Mgmt Ltd Liability Corp accumulated 38,910 shares or 0% of the stock. Bnp Paribas Arbitrage invested in 17,476 shares or 0% of the stock. Moreover, Automobile Association has 0% invested in Endologix, Inc. (NASDAQ:ELGX). Goldman Sachs Incorporated has invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Bankshares Of Mellon Corporation invested in 0% or 364,478 shares. Bluecrest Capital Mgmt Limited accumulated 98,687 shares. Aperio Ltd Liability Co, a California-based fund reported 18,796 shares. Manufacturers Life Ins The stated it has 67,076 shares. Amalgamated National Bank owns 10,898 shares. Wells Fargo & Mn has 77,744 shares for 0% of their portfolio. Metropolitan Life accumulated 19,743 shares. C Grp Incorporated Holding A S stated it has 297,978 shares or 0.02% of all its holdings. Citigroup reported 723 shares. Nea Mngmt Ltd Liability Co has 2.49 million shares. Public Employees Retirement Association Of Colorado reported 20,710 shares stake.

Since May 29, 2018, it had 0 buys, and 1 sale for $91 activity.

The stock of Endologix, Inc. (NASDAQ:ELGX) hit a new 52-week high and has $6.64 target or 5.00 % above today’s $6.32 share price. The 9 months bullish chart indicates low risk for the $530.95 million company. The 1-year high was reported on Jun, 18 by Barchart.com. If the $6.64 price target is reached, the company will be worth $26.55 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 4.10% or $0.27 during the last trading session, reaching $6.32. About 460,464 shares traded. Endologix, Inc. (NASDAQ:ELGX) has risen 18.20% since June 18, 2017 and is uptrending. It has outperformed by 5.63% the S&P500.

Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on August, 1. They expect $-0.19 EPS, down 90.00 % or $0.09 from last year’s $-0.1 per share. After $-0.16 actual EPS reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts 18.75 % negative EPS growth.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 4 analysts covering Endologix (NASDAQ:ELGX), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Endologix had 5 analyst reports since January 2, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Monday, May 21 with “Hold”. The stock of Endologix, Inc. (NASDAQ:ELGX) has “Hold” rating given on Thursday, February 22 by Stifel Nicolaus. The firm has “Underweight” rating by JP Morgan given on Tuesday, January 2.

More news for Endologix, Inc. (NASDAQ:ELGX) were recently published by: Ocbj.com, which released: “Midday Stock Roundup” on May 21, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” and published on June 15, 2018 is yet another important article.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $530.95 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

Endologix, Inc. (NASDAQ:ELGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: